ENSC
Ensysce Biosciences, Inc.
ENSC's outlook is improving, though it still trails on the overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ENSC overall, supported by stronger fundamentals.
ENSC Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
ENSC's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ENSC PE Valuation
ENSC has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ENSC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect ENSC's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ENSC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.75 | +$8.47 |
| Q2 2026 | -$2.52 | +$9.36 |
| Q1 2026 | -$3.11 | +$11.28 |
| Q4 2025 | -$3.98 | +$17.27 |
| Q3 2025 | -$14.22 | +$7.68 |
| Q2 2025 | -$11.88 | +$24.12 |
| Q1 2025 | -$14.39 | +$33.01 |
| Q4 2024 | -$21.25 | +$49.10 |
ENSC lost $5.75 per share over the past year, a smaller loss than the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ENSC on earnings quality, reporting a profit while its opponent remains loss making.
ENSC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.2M | +342% |
| Q2 2026 | $1.2M | -15% |
| Q1 2026 | $961K | -27% |
| Q4 2025 | $1.9M | +44% |
| Q3 2025 | $493.1K | -86% |
| Q2 2025 | $1.4M | +654% |
| Q1 2025 | $1.3M | +332% |
| Q4 2024 | $1.3M | +153% |
ENSC's revenue is recovering but still below its 2024 peak: $2M last quarter, up 342% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3781% | -3023 points |
| Q2 2026 | -221% | -94 points |
| Q1 2026 | -371% | -222 points |
| Q4 2025 | -148% | +127 points |
| Q3 2025 | -759% | -778 points |
| Q2 2025 | -128% | +948 points |
| Q1 2025 | -149% | +454 points |
| Q4 2024 | -274% | +338 points |
ENSC's operating margin was −3781% last quarter, down 3023 points from the same quarter a year ago, near the bottom of its range since 2021.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ENSC on profitability, with a higher operating margin.
ENSC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | +$744.4K |
| Q1 2026 | -$3.5M | -$1.8M |
| Q4 2025 | -$1.5M | -$761.7K |
| Q2 2025 | -$2.7M | -$397K |
| Q1 2025 | -$1.7M | +$1.7M |
| Q4 2024 | -$764.1K | +$1M |
| Q3 2024 | -$1M | +$1.2M |
| Q2 2024 | -$2.3M | +$798.7K |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with ENSC at up 6.3%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ENSC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +40% | +5.2M shares |
| 1 year | +530% | +15.3M shares |
| 3 years | +25787% | +18.1M shares |
| 5 years | +985979% | +18.2M shares |
| Available history | +1077056% | +18.2M shares |
ENSC has 18M diluted shares, up 530% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | $136.3M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over ENSC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ENSC Net Leverage
ENSC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ENSC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 20.9 | Neutral |
ENSC's weekly RSI is 45 (neutral) and its Stochastic is 21 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ENSC PE vs Healthcare Sector
| Metric | ENSC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ENSC has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ENSC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.43 | 9.3% below |
| 20 week MA | $0.40 | 2.5% below |
| 50 week MA | $0.53 | 26% below |
| 100 week MA | $1.97 | 80% below |
| 200 week MA | $14.8 | 97% below |
ENSC is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ENSC on trend strength, trading above more of its moving averages.
ENSC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37,224.0 | $47,808.0 | +28% |
| 2021 | $47,808.0 | $18,432.0 | -61% |
| 2022 | $18,432.0 | $129.6 | -99% |
| 2023 | $129.6 | $15.9 | -88% |
| 2024 | $15.9 | $8.88 | -44% |
| 2025 | $8.88 | $1.10 | -88% |
| 2026 YTD | $1.10 | $0.39 | -65% |
ENSC has finished five years in a row lower, and it's down 65% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ENSC on returns for 2026, with the stronger performance.